MEI Pharma

MEI Pharma is a biotechnology company dedicated to developing best-in-class cancer therapies, particularly targeting hematologic malignancies and solid tumors. The company is committed to overcoming known drug resistance mechanisms through novel and differentiated treatments. Key programs in their pipeline include Voruciclib and ME-344. MEI Pharma has reported initial data from clinical studies evaluating ME-344 in combination with Bevacizumab (Avastin®) in patients with relapsed metastatic colorectal cancer. Located at 11455 El Camino Real, Suite 250, San Diego, CA 92130, MEI Pharma provides information and resources for patients and caregivers and offers clinical trials as part of their development pipeline. The company publishes annual reports and quarterly results, aligning its strategy to advance Voruciclib and ME-344. MEI Pharma is committed to delivering benefits to patients through its oncology focus and uses data-driven decisions to create value. Additionally, the company engages in collaborations to enhance its research and development efforts.